Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Fibroblast Growth Factor Receptor (FGFR) signaling pathways are implicated in various cancers.
• Aberrant FGFR activation due to mutations, amplifications, or translocations drives tumor growth and progression.
• Targeting FGFR represents a promising therapeutic strategy in oncology.

Purpose of the Study:

• To identify and characterize novel small molecule inhibitors targeting the FGFR family of receptor tyrosine kinases.
• To evaluate the selectivity of these inhibitors against closely related kinases like VEGFR2.
• To define the pharmacologic profile of these inhibitors in FGFR-altered cancer models for potential clinical utility.

Main Methods:

• Identification and characterization of novel FGFR inhibitors.
• In vitro kinase assays to assess inhibitory activity and selectivity.
• Cell-based assays using human tumor cell lines with known FGFR alterations (mutations, amplifications, translocations).
• In vivo studies to evaluate efficacy and pharmacologic properties.

Main Results:

• Discovery of two novel compounds with potent inhibitory activity against the FGFR family.
• Demonstrated selective inhibition of FGFR over VEGFR2 in both cell lines and in vivo models.
• Characterization of the pharmacologic profile across a panel of human tumor cell lines with diverse FGFR alterations.
• Established a clear link between specific FGFR alterations and sensitivity to the novel inhibitors.

Conclusions:

• The identified compounds are selective FGFR inhibitors with a defined pharmacologic profile.
• These inhibitors show potential for clinical application in treating cancers with activating FGFR alterations.
• Further development of these FGFR inhibitors could lead to new targeted therapies for specific cancer types.